Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131870 | 0.80 | ALDH1A1 (0.46) | ALOX12MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL7726674 | 0.79 | MAOB (0.59) | ALOX15LMNAHTTALDH1A1CYP2C9 | |
| SCHEMBL9647072 | 0.78 | PARP10 (0.50) | ALDH1A1POLBCES2CYP1A2CYP2C19 | |
| SCHEMBL13963701 | 0.78 | PDE10A (0.48) | ALOX15ALOX12MAPTHTTALDH1A1 | |
| SCHEMBL28146640 | 0.78 | TRPA1 (0.48) | ALOX15ALOX12MAPTLMNAALDH1A1 | |
| SCHEMBL74689 | 0.77 | MAOB (0.61) | ALOX15ALOX12HTTALDH1A1HPGD | |
| SCHEMBL29744489 | 0.77 | MAOB (0.61) | ALOX15ALOX12HTTALDH1A1HPGD | |
| SCHEMBL30688242 | 0.76 | ALOX15 (0.66) | ALOX15ALOX12MAPTSMN1; SMN2LMNA | |
| SCHEMBL347489 | 0.76 | ALOX15 (0.66) | ALOX15ALOX12MAPTSMN1; SMN2LMNA | |
| SCHEMBL17744335 | 0.76 | HSD17B10 (0.45) | ALOX15ALOX12MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| WO-2013016720-A2 | NOVEL SUBSTITUTED BIARYLHETEROCYCLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | GERINDA THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013016720-A2 | NOVEL SUBSTITUTED BIARYLHETEROCYCLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | GERINDA THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| CN-101374844-B | Pyrrolopyridazinone compound | UBE INDUSTRIES | 2012-10-24 | — | — | CN | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| CN-101233129-A | Substituted biaryl heterocyclic derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | PFAHL FAMILY TRUST (US) | 2008-07-30 | — | — | CN | disclosed |
| EP-1896462-A2 | SUBSTITUTED BIARYLHETEROCYCLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | The Pfahl Family Trust (Dated 9 July 1996) (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006130613-A2 | SUBSTITUTED BIARYLHETEROCYCLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | THE PFAHL FAMILY TRUST (DATED 9 JULY 1996) (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | AR 1474/4885ALOX15 4734/4885ALOX12 4791/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | AR 1994/4885ALOX15 81/4885ALOX12 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.